Tafolecimab [2225109-03-3]

TargetMol Chemicals

Tafolecimab

9

2225109-03-3

Antibody

Research Use Only

Tafolecimab

Tafolecimab (IBI-306), a human IgG2 monoclonal antibody, specifically targets and binds to PCSK-9, thus inhibiting PCSK-9-mediated endocytosis of the LDL receptor. This action enhances the clearance of LDL-C, resulting in a decrease in LDL-C levels. Tafolecimab has potential applications in hypercholesterolemia research [1].

3 years

-20°C

12352203